Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about GSK plc
GSK plc News
GSK plc Quantitative Score
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
GSK plc Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
GSK plc Financials
Table Compare
Compare GSK metrics with: | |||
|---|---|---|---|
Earnings & Growth | GSK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GSK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GSK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GSK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
GSK plc Income
GSK plc Balance Sheet
GSK plc Cash Flow
GSK plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
GSK plc Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 1.6045 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-07-10 | 0.42909 | Quarterly |
| 2025-04-10 | 0.40065 | Quarterly |
| 2025-01-09 | 0.38905 | Quarterly |
| 2024-10-10 | 0.38567 | Quarterly |
| 2024-07-11 | 0.37619 | Quarterly |
Historical Market Cap
Shares Outstanding
GSK plc Executives
| Name | Role |
|---|---|
| Ms. Emma Natasha Walmsley | Chief Executive Officer & Director |
| Ms. Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director |
| Dr. Jesse L. Goodman M.D., M.P.H. | Scientific & Medical Expert |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D |
| Mr. James Ford | Senior Vice President & Group General Counsel of Legal & Compliance |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Emma Natasha Walmsley | Chief Executive Officer & Director | Female | 1969 | 5.98M |
| Ms. Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director | Female | 1962 | 5.54M |
| Dr. Jesse L. Goodman M.D., M.P.H. | Scientific & Medical Expert | 1951 | 228K | |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D | Male | -- | |
| Mr. James Ford | Senior Vice President & Group General Counsel of Legal & Compliance | Male | -- |